Afternoon, and welcome to Supernus Pharmaceuticals' Q1 2026 financial results conference call. At this time, all participants are in a listen-only mode. Later, we will conduct a question and answer session. Instructions will follow at that time. As a reminder, this conference is being recorded. I would now like to turn the conference over to Peter Vozzo of ICR Healthcare, investor relations representative for Supernus Pharmaceuticals. You may begin. Thank you. Good afternoon, everyone, and thank you for joining us today for Supernus Pharmaceuticals' Q1 2026 financial results conference call. Today, after the close of the market, the company issued a press release announcing these results. On the call with me today are Supernus' Chief Executive Officer, Jack Khattar, and Chief Financial Officer, Tim Gannon. Today's call is being made available via the investor relations section of the company's website at www.ir.supernus.com. During the course of this call, management may make certain forward-looking statements regarding future events and the company's future performance. These forward-looking statements reflect Supernus' current perspective on existing trends and information. Any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, including those noted in the risk factor section of the company's latest SEC filings. Actual results may differ materially from those projected in these forward-looking statements. For the benefit of those of you who may be listening to the replay, this call is being held and recorded on May fifth, 2026. Since then, the company may have made additional announcements related to the topics discussed. Please reference the company's most recent press releases and current filings with the SEC. Supernus declines any obligation to update these forward-looking statements except as required by applicable securities laws. I'll now turn the call over to Jack. Thank you, Peter, and thanks everyone for taking the time to join us on today's call. Supernus' Q1 results reflect a strong start to the year, including a 56% year-over-year increase in combined revenues of our growth products and an 11% year-over-year increase in adjusted operating earnings. Starting with ONAPGO, during the Q1, ONAPGO generated net sales of $8.4 million, reflecting a partial benefit from the resumption of new patient initiations in February 2026. We are pleased with the rebound in the business since we resumed patient initiations, with some of the metrics in March reaching or even exceeding levels achieved before the supply constraints. For instance, prescriptions in March reached 463, exceeding the level reached in October 2025 before the supply constraints. Also, the number of prescribers in a single month with shipments to patients increased in March to the highest level since the launch of the product. Overall, more than 645 prescribers have submitted approximately 2,200 enrollment forms since the launch of the product through the end of April 2026. We are also pleased with the progress with the second supplier on ONAPGO. We expect regulatory submission to the FDA in the Q3 of this year, with potential approval before mid-year 2027. Switching now to ZURZUVAE, Supernus reported $27.6 million in collaboration revenues in the Q1. Full Q1 2026 U.S. sales of ZURZUVAE, as reported by Biogen, increased approximately 100% compared to the same period in 2025. In the Q1 of 2026, ZURZUVAE saw strong growth of 82% and 73% in written prescriptions and number of prescribers, respectively, compared to the same period last year. Since launch, 85% of the prescriptions have come from repeat prescribers, and more than 29,000 patients have been treated with ZURZUVAE. Regarding Qelbree in the Q1, and as reported by IQVIA, prescriptions grew by 19% compared to the same period last year, outpacing the 10% growth in the total ADHD market. Net sales of $78 million represented a strong 20% increase over the Q1 last year. Despite typical Q1 headwinds, Qelbree's growth continues to be solid and is coming from both patient populations, with adult prescription growth of 27% and pediatric prescription growth of 15%. In addition, the total quarterly number of prescribers for Qelbree reached a high of approximately 43,000, with adult prescribers for the first time surpassing the number of pediatric prescribers. Switching now to GOCOVRI for the Q1 of 2026, net sales reached $35.2 million, increasing by 15% compared to the same quarter in 2025. Total number of prescriptions grew by 7% in the Q1 of 2026 compared to the same period last year. Moving on to R&D, the follow on Phase IIb randomized double-blind placebo-controlled trial with SPN-820 in approximately 200 adults with major depressive disorder is ongoing. This study will examine the safety and tolerability of SPN-820 and its efficacy at a dose of 2,400 milligrams given intermittently twice per week as an adjunctive treatment to the current baseline antidepressant therapy.Our phase IIb randomized double-blind placebo-controlled study of SPN-817 is also ongoing, with a targeted enrollment of approximately 258 adult patients with treatment-resistant focal seizures. This trial utilizes 3 milligram and 4 milligram twice-daily doses. For SPN-443, our novel stimulant ADHD product candidate, we expect to initiate a phase I single ascending and multiple ascending dose study in adult healthy volunteers in the H2 of 2026. Finally, corporate development will continue to be a top priority for us as we look for additional strategic opportunities to further strengthen our future growth and leadership position in CNS through revenue-generating products or late-stage pipeline product candidates. With that, I will now turn the call over to Tim. Thank you, Jack. Good afternoon, everyone. As I review our Q1 2026 results, please refer to today's press release and 10-Q that was filed earlier today. We achieved total revenue of $207.7 million for the Q1 of 2026, an increase of 39% compared to the same quarter last year. Total revenues were comprised of revenues from our commercial products, including ZURZUVAE, collaboration revenues, and royalty, licensing, and other revenues. Revenues from commercial products increased to $178 million, a 26% increase compared to the same quarter last year. This increase in revenues from commercial products was primarily due to the increase in net sales of our growth products, Qelbree, GOCOVRI, and ONAPGO, as well as the addition of collaboration revenues from ZURZUVAE. In addition, revenues from royalty and licensing and other revenues were $29.3 million. This includes $20 million of licensing revenues related to the achievement of a commercial milestone under the company's collaboration agreement with Shionogi. For the Q1 of 2026, combined R&D and SG&A expenses were $164.6 million, as compared to $116.9 million for the same quarter last year. This increase was primarily due to an increase in SG&A expenses associated with the collaboration agreement with Biogen. Operating loss on a GAAP basis for the Q1 of 2026 was $8.3 million, as compared to an operating loss of $10.3 million for the same quarter last year. The change was primarily due to higher revenues, partially offset by an increase in SG&A expenses associated with the collaboration agreement with Biogen. GAAP net loss was $2.3 million for the Q1 of 2026, or net loss per share of $0.04, compared to GAAP net loss of $11.8 million, or $0.21 per diluted share in the same period last year. On a non-GAAP basis, which excludes amortization of intangibles, share-based compensation, contingent consideration, and depreciation, adjusted operating earnings for the Q1 of 2026 was $28.7 million, compared to $25.9 million in the same quarter of last year. As of March 31st, 2026, the company had approximately $384 million in cash equivalents, and marketable securities, compared to $309 million as of December 31st, 2025. This increase was primarily due to cash generated from operations, the timing of Medicaid payments, and the Shionogi-related commercial milestones. Company's balance sheet remains strong, with no debt and significant financial flexibility for potential M&A and other growth opportunities. Turning to guidance. For full year 2026, the company reiterates its financial guidance for total revenues, combined R&D and SG&A expenses, and non-GAAP operating earnings. We expect total revenues to range from $840 million-$870 million, comprised of commercial product revenues and royalty and licensing revenues. For the full year 2026, we expect combined R&D and SG&A expenses to range from $620 million-$650 million. We expect full year operating earnings in the range of $0-$30 million. Finally, we expect non-GAAP operating earnings to range from $140 million-$170 million. Please refer to the earnings press release issued prior to this call that identifies the various ranges of reconciling items between GAAP and non-GAAP. With that, I will now turn the call back over to the operator for Q&A. Operator? Thank you. At this time, we will conduct a question and answer session. As a reminder, to ask a question you will need to press star one one on your telephone and wait for your name to be announced. To withdraw your question, please press star one one again. Please stand by, while we compile the Q&A roster. Our first question comes from Andrew Tsai from Jefferies. Your line is now open. Hi, thanks for the updates. Thanks for taking my questions. Specifically on ONAPGO, it's great to see that you have 2,200 start forms now, up from 1,800. In January. Ultimately, what percentage of those patients or start forms do you think you will be ultimately converted to a patient, a paying patient? Can you remind us how many weeks it can take from a start form to a paying patient, how long that could take? Thank you. Yeah. On an average, from the time you get a form until you have a shipment, I mean, you could lose somewhere in the 40%-45% of these, you know, patients in the process for all kind of reasons. Whether it's, you know, change in the medical condition of the patient over time, the insurance issue, any of these reasons, you know, eventually or just lack of response sometimes because a lot of these forms don't have all the completed information, so you're calling the patient and trying to get more information from them to be able to process it. Sometimes you just don't call back. As far as the period of time, I mean, it could take several weeks. As we, you know, go through this process over time, of course, we're always looking at different bottlenecks and try to streamline and improve the process. It is several weeks, you know, for somebody to have the form submitted until finally they get the product shipped. Got it. Thank you. Following up on that, to get to your ONAPGO guidance, the high end of $75 million, mathematically, you're gonna be needing more than 700 patients on therapy. If I did 2,200, 50% conversion, you know, that would be at that over 1,000 patients potentially on ONAPGO. It looks like you can get there. Can you remind us how many patients are still on ONAPGO today? And when could you expect most of those kinda hypothetical patients to get on drug, you know, should it be within the next 3-6 months then? Thank you. Yeah. I mean, the high end of our guidance is, you know, the $70 million. You're thinking about it the right way. Yes. I mean, that could translate to somewhere around on an average, about 700 patients, you know, that you need to have around 700 patients throughout the whole year, clearly, to give you the $70 million, you know, in sales. The thing is, with the 2,200, you have to remember that's a number that is launched to date. That is not 2,200, you know, in 2026 obviously, right? It would be interesting to see how many we generate this year and how many out of the 20 or whatever is left actually out of the 2,200. If we look at the backlog right now, we have probably somewhere around 570, you know, give or take patients in the queue versus, you know, last time we talked, it was around 700. We are going through the backlog, and we're actually improving as time goes on. We're improving our number of patients that are being processed per week. Remember, I mean, we just restarted the whole machinery, so to speak, or the whole process started, you know, middle to end of February, so to speak. It's taken us March, and we've been very happy with the progress, you know, the team has made through March, really getting us to very high levels. As I mentioned in my previous remarks, even exceeding, you know, performance metrics, exceeding those who were before the supply constraints. Things are really on the uptick. We're pretty happy with the rebound in the business, how we're processing these forms, how many of these forms we're able to translate into real patients and real shipments. We maintain the guidance, of course, because we would like to see another full quarter. Q1, as I mentioned in my remarks, was really a partial quarter. It wasn't really a full quarter, right? Let's see a full quarter and how quickly we can go through this backlog. In the Q1, we only really benefited from March, so to speak. February was very partial and very minimal initiations in January, therefore, it's not a true reflection of a full quarter with the business rebounding. We're very happy with how things are moving along across, you know, several metrics. With the demand continuing to be strong, as you pointed out with the 2,200 forms, but also with the way the team is processing these forms and trying to minimize, you know, the drop-offs and the losses throughout the process. We feel still pretty good, obviously, and that's why we didn't change the guidance. Still pretty good about the $45 million-$70 million guidance on ONAPGO. Very good. Thank you. Thank you. Our next question comes from the line of David Amsellem from Piper Sandler. Your line is open. Hi. Yes, this is Alex on for David. Thanks for taking our questions. First one, sort of, jumping off of the last question regarding the guidance range for ONAPGO and the assumptions to get to the top end of the, of the range and the number of patients. Can you maybe speak to what you're seeing in terms of patient persistence for patients who are getting drugs? Secondly, regarding ZURZUVAE, can you maybe speak to how you're thinking about the growth runway of the product? Thank you. Yeah. Regarding ZURZUVAE, as I mentioned in my remarks, I mean, really pleased with the performance of the product. If you look at the true fundamental metrics as far as prescriptions, number of prescribers, I mean, we're really broadening the prescriber base, and we've been very successful with our partner, Eisai, in doing that. Of course, the prescriptions grew a very healthy 82% in the quarter versus last year. As far as penetration, we're still in the real early innings on this product, as we mentioned previous quarters. The potential of the product is fairly big. You know, every year you have around 500,000 women who experience these symptoms. As I mentioned again earlier, only 29,000 patients have been treated with ZURZUVAE since launching, you know, and we're into year three right now. We have a long way to go with ZURZUVAE, and we're very happy with the momentum of the brand. Of course, we also started significant efforts on the DTC side and other programs. We have, you know, pretty nice expectations of growth from the product. Regarding, if I understood your question on ONAPGO, is it really the patient profile and the kind of patient, you know, we're getting on ONAPGO? It looks like we're starting to get, you know, some feel for who is that patient. We don't have a complete full picture yet because as you would imagine with a new product, it evolves over time. Some of the early indicators, you know, patients tend to be more on the younger side as far as age and/or, and/or the disease, meaning, you know, they haven't been diagnosed for a long, long time. They tend to be active. They tend, you know, to really be looking for specifically from a physician perspective, they're looking for something different than a levodopa carbidopa. That's the kind of patient profile that seems to be emerging right now as we speak on the ONAPGO side. Thank you. What are you seeing in terms of patient persistence for ONAPGO? Yeah. It's a little bit too early for us because we got the disruption in the supply and so forth. Actually, we were pretty happy with, you know, the refills and how many patients stayed with us around the time of the supply constraint. We do have dropouts that are fairly consistent with the clinical study, maybe a little bit more. We're watching it very carefully. Typically these dropouts occur when you have the titration and how well the titration has happened. With apomorphine, you have to do titration very slowly and with a very starting with lower doses. You can't jump in pretty quickly into high doses on apomorphine. Depending on how that is happening and how the patient is responding to that, Once they go through that titration, typically they tend to stay with it and be pretty happy and pleased with it. That's been the experience, you know, that historically has been in Europe. Thank you. Thank you. Our next question comes from the line of Kristen Kluska. Pre, start of the year Kristen Kluska from Cantor. I apologize. It's okay. Yeah. Hi, everyone. Congrats on a great start to calendar year 2026 here. Just on ONAPGO, as we think about the mid 2027 approval, how are you working with your partners out in Europe about thinking about what the demand might look like in 2027 onwards to be able to work with them to meet that criteria? When we think about the U.S. right now in terms of the patients that are getting on therapy, given that these capacity strengths are still there to an extent, are you seeing that physicians are prioritizing certain patients over another, just knowing that they might not be able to get their hands on enough supply for all of the patients they'd want to treat? Yeah. Regarding the last question, I mean, we haven't detected anything specific that because of, you know, the previous supply constraint, that they're using the product on a different patient or one patient versus another. We can't really at this point, again, answer that question specifically. Overall, regarding your other part of the question on the supplier and 2027 demand and so forth, I mean, we do have a plan with our second supplier and also the current supplier, because depending on the timing as to when the second supplier comes into in 2027, to meet the demand of 2027, certainly. That's really how we align all that and lay over the current supply, the second supply, and look at the demand in total and make sure that we are covered from either one of them and/or both at the same time. The second supplier also, I should say, have multiple of the capacity that the current supplier has. Once the second supplier is online, we will feel pretty good about 2027. I did mention once earlier, you know, we're even working on another supplier as a backup as well, in addition to the second supplier. We're giving up a lot of the, you know, backups from a supply perspective to make sure we meet the demand not only in 2027, of course, and you know, several years beyond that. Okay, thanks. On ZURZUVAE, how are you seeing adoption in line with the prescribing? Meaning, like, are you seeing some patients are coming back for second cycle of it? What% of patients are completing the 14-day treatment course? What I'm trying to allude to is like, how close to the recommendations are you seeing this real-time? Thanks again. Yeah, with ZURZUVAE typically, I mean, people stick with the 14-course therapy. It is a short-term therapy to start with, so it's unlikely that people are going to quit on it. And especially when they start seeing the benefit early, pretty quickly by day three. That obviously even reinforces it and encourages them to finish, you know, the 14-day therapy. And with ZURZUVAE, you know, obviously it's a very different kind of business. You don't have refills. You know, of course, unless mom, you know, gets pregnant again and, you know, it's another year or cycle, so to speak, and she happens to have also PPD second time, you know, with the second pregnancy. Normally there is no relapse or anything like that for them to come back, and cycle through it again. Thanks, Jack. Thank you. Our next question comes from the line of Vishwesh Shah from TD Cowen. Your line is now open. Hi. Thank you. Congrats to you guys on another great quarter. On Qelbree, what are you seeing in terms of some of the adoption trends right now? You commented on some of the adults, trying out, Qelbree. Is that the shift in focus now? You know, what do you think will drive growth in adoption through the rest of the year? Thanks. Yeah. We're actually very excited on Qelbree and what we really saw in the Q1, and it's a pretty interesting dynamics in a very positive way, specifically in the adult segment of the market. There are several things that I would, you know, pretty much emphasize on Qelbree. Clearly the adult growth has been now outpacing pediatric growth for a number of quarters, actually. This is not the Q1 it happens. We're very pleased with the fact that, you know, the adult continues to grow because it is the biggest segment of the market naturally, and you wanna be, you wanna penetrate that segment as much as possible and be very successful in it for the continued future growth of the product. For example, I'll give you another metric. If you look at new prescriptions in the Q1 of 2026, adult again grew by 27%. This is in new prescriptions, not total prescriptions. Pediatrics continue to be strong also with 16% growth. The interesting thing is, I mean, we have been emphasizing adult. We've been putting, you know, a little bit more emphasis on adult, especially when we are out of this back to school season because we rotate, of course, the emphasis, we rotate the resources. In the back to school season, clearly we put more of a push on pediatrics, but we don't neglect adults. When we are out of the back to school season, we try to take advantage of the growth in the adult market because from a market point of view, in the total market, adult also continues to be the fastest segment that is growing. We want to take advantage of that as well. We're pretty pleased with that. As I mentioned earlier, this is for the first time now, number of prescribers in the adult have surpassed our number of prescribers in pediatrics. Really jumped pretty quickly, noticeably, in the, in this Q1. We were very pleased to see that. Also from the patient perspective, what's really happening, which we're encouraged about also, is the fact that the patient profile, and you would expect that typically in a brand as it, you know, stays on the market for a while, and now we're into year 6 pretty much. You know, in May, we're in year 6 of the brand. The patient profile is broadening, so it's not anymore, you know, some of the early low-hanging fruit that you're getting basically. What I mean by that is you're really getting a much broader types of patients into the franchise, and physicians are starting to think of so many different types of patients and needs out there that Qelbree could be the answer for. For example, you know, patients who of course are intolerant to stimulants. Something interesting emerging is patients are really looking for all-day coverage. A lot of the adults, we know it as a fact, you know, when they use stimulants, even if they use controlled release stimulants, so many of them have to supplement at the end of the day with immediate release stimulant to give them that full day coverage. With Qelbree, you don't need any of that. You just need to take it once a day, whether at night or in the morning, it will give you full day coverage. I think physicians over time, as they have more experience with the product, they're finding more ways to use Qelbree as a true solution for a lot of their patients. Of course, you know, those who are partial responders to stimulants. I mean, stimulants work, but they don't work for everybody, and sometimes we forget that. You know, a lot of physicians are using it for those partial responders, you know, to stimulants and then the complex ADHD and of course, that comes with time, you know, as we generate more data around the product and the potential use of the product with comorbidities and so forth. More and more patients are starting to understand that Qelbree could really play a role with these patients who have that, what we call complex ADHD because of the serotonin modulation, you know, and the very unique multimodal activity and pharmacodynamic profile of Qelbree. A lot of very exciting things continue to happen there and really a lot of momentum in the brand. Thanks. Yeah, thanks so much for all the details. On ONAPGO, what dynamics are you seeing between patients opting for ONAPGO versus VYALEV? What kind of competitive dynamics are you seeing there? Yeah. I mean, I mentioned very quickly, the first cut-off typically is patients who have been on levodopa carbidopa, and the physician may not see any incremental additional benefit for the patient to stay on that drug. Therefore, they could potentially benefit more from something else, you know, a different drug, different mechanism, different molecule, and therefore they would go and turn to something like ONAPGO. Vice versa, if the physician feels that the patient may still benefit from some levodopa carbidopa, maybe for another year or two, then they might consider ONAPGO. They might go, you know, towards something like VYALEV, something else instead of ONAPGO. That's the first, you know, thing that obviously a physician is assessing. Interesting from our research, it looks like our patient profile tends to be on the younger side, active, side, earlier in the disease, versus the VYALEV patient tends to be a little bit more on the older side. You know, we're trying to dig into deeper into this to really understand what's behind, you know, some of that. Some of the folks who may need and have very difficult time at night, they may choose VYALEV because you put VYALEV through the night. With our product, I mean, you get pretty much a similar efficacy on reducing off-time, but you don't have to wear it, you know, 24 hours. But with VYALEV, you have to wear it 24 hours to give you pretty much similar type of efficacy. There are different patients that are emerging that could be really different candidates for either ONAPGO or VYALEV. Got it. Thank you very much. Thank you. Our next question comes from Annabel Samimy from Stifel. Hi, this is Jack on for Annabel. Thanks for taking our questions, and congrats on the quarter. On ZURZUVAE, I know that there are the active DTC campaign running right now. Clearly, the product has been doing very well overall. Do you have any additional insights or color on feedback from that and how patients are responding to the DTC campaign compared to maybe a more direct physician recommendation? Yeah. Unfortunately, no, because it's really early, you know, to be able to have a good read. I mean, we just started it, and you need several months of data to get a meaningful read on a response if you're getting a good response from the DTC. The only thing I can tell you is kind of anecdotal, you know, feedback from physicians, from patients who have seen it or, I mean, they really relate to it. The messages, the communication out of the commercial and so forth, you know, we've received very positive feedback on that. In the end, it has to turn into prescriptions, of course. I mean, that's really the key measure at the end of the day, and it's pretty early for us right now, you know, to say anything as far as the impact of the campaign. Certainly, I mean, we, I mean, the effort there is clearly to provide significant education because this is a market that needs a lot of education on the consumer side as well as on the, you know, healthcare provider side. That's what we're trying to do. We've been building the market, and it takes a while to build the market, and that's something that needs to be, you know, continued to be invested in. Again, initial signals, which are more anecdotal, seems to be, yeah, you know, positive. No, no, very helpful. Then just quickly, given your success with that collaboration, is your current M&A appetite kind of more focused on maybe something similar, like a revenue-generating partnership or more on acquisition of wholly owned late-stage assets? Are there any shifting preferences there, or are you still kind of agnostic to any option? No, I mean, our priority is revenue-generating assets that we can wholly own it and, you know, obviously, build it and grow it from whatever it is at the time we buy it. And then the second priority, if it's not revenue-generating, we're looking at assets that are fairly late stage. So these assets could potentially be launched in, between a year to three years, you know, from the time we acquired them. That's really what we're very much focused on and fairly agnostic in the CNS space and of course, women's health as well. Great. Thank you. Thank you. Our next question comes from Qi Fang from Bank of America. Your line is now open. Hey, guys. Thanks for taking our question. I want to follow up on the bringing the second supplier online for ONAPGO. Did you get a chance to meet with the FDA to get any sort of feedback or alignment on some of the path of getting the approval? Did any of the feedback help inform the timeline guidance you provided today? What I'm wondering is whether there's any accelerated path like rolling submission relative to your Q3 filing guidance. I guess on the other side of the things, on approval timeline you've guided to by mid 2027. I recall on the last earnings call you talked about review timeline could be arranged somewhere in the six to nine month range. I'm curious if you have any better clarity on the review timeline now, if you have already met with the FDA. I have a follow-up after that. Yeah, sure. Yes, the answer is yes. We've been very much in touch with the FDA on an ongoing basis. Yes, the guidance we just gave today has been and is based on the conversations we've had with the FDA. If we do file, which we said we're expecting to file in the Q3, we expect the approval, again, consistent with what we said before, could be six months to nine months. That will fall at the outer, you know, at the upper end of the timeline in the nine months. That means mid-year 2027. If it does take only six months for review, that obviously will be within that, you know, earlier than that. That's pretty consistent. The FDA was consistent with their feedback, you know, with all the discussions we've had with them. Depending when exactly we file, you know, July, August, September, whatever, and then you add six months to it, or it could take nine months, I mean, that's really within that frame that we just gave today. Great. My follow-up is, obviously the second supplier already has experience supplying the product in Europe. Given the sometimes idiosyncratic nature of the agency handing out manufacturing issue citations and the second, more broadly, can you talk about the confidence level of timely clearance of the second supplier? We have no indication that something could happen that could really would derail this timeline from that perspective. Clearly Once we submit the package, they have to of course review the data and so forth, and then they have to also schedule the inspection. As far as we know, they have been doing inspections, although it is outside the U.S. in Europe, so we don't see, and we're not aware of anything that could hinder that. That's why we continue to keep the timeline fluid, saying 6 to 9 months because of that specifically. We're not aware of anything that could tell us that this could derail this thing completely and make it not an option for us at all. We're pretty confident, you know, that we should be able to meet that timeline and secure that second supplier. Okay, great. Thanks so much for answering our question. Thank you. I am showing no further questions at this time. I would now like to turn it back over to Peter Vozzo. Thank you for joining us on this call today. 2026 is off to a great start. We have positive momentum across our business, and we continue to generate strong cash flows behind the strength of our growth products and through the efficiency of our operations. We look forward to continued strong growth and execution on our growth products throughout the year. Thanks again for joining us this afternoon. We look forward to providing you with updates throughout the year. Thank you for your participation in today's conference. This does conclude the program. You may now disconnect.